Advancing antibody discovery with function-focused profiling at the single-cell level

Antibody discovery has traditionally prioritised binding over function. This poster presents a next-generation droplet microfluidics platform, Envisia, that performs highly controlled, sequential single-cell functional assays, helping researchers bring function into focus and advance only the most promising candidates.

‍

Data presented includes a hybridoma spiking study detecting rare antibody-secreting cells, rapid single B cell loading of up to 12,000 cells in under 90 minutes, and real-time tracking distinguishing true hits from false positives.

‍

Download this poster to see how Envisia supports end-to-end antibody discovery in under a day.

‍